Patrick Hwu, President and CEO at Moffitt Cancer Center, shared on X:
“Can low-dose gut irradiation enhance the effectiveness of PD-L1 blockade in metastatic cancer? PD-L1 blockade therapy works by lifting the ‘brakes’ on the immune system, helping T cells attack tumors more effectively, but not all patients respond.
In this study, Chen, Eric Deutsc, and other researchers Gustave Roussy tested intestinal low-dose radiotherapy (ILDR) in patients who had previously shown resistance to anti-PD-1 therapy. The results suggest ILDR, followed by restarting immunotherapy, may boost response rates.
This approach offers a potential new way to overcome resistance by modulating the gut environment.”
Authors: Jianzhou Chen et al.
